Clinical-stage opportunity Cornerstone Pharmaceuticals is a clinical-stage metabolic oncology company with a lead drug CPI-613 in multiple Phase I to II studies, indicating early collaboration potential with CROs, contract manufacturers, and clinical trial service providers to advance trials and expand indications.

Specialized metabolism focus The firm targets cancer cell energy metabolism and mitochondrial processes, presenting a niche for suppliers of specialized assay development, biomarker services, and metabolic imaging partners to support mechanism-of-action studies and patient stratification.

Strategic tech fit Their tech stack including Cloudflare Bot Management, Google Tag Manager, and PHP-based web infrastructure suggests potential interest in cybersecurity, data privacy, and web analytics services to scale their digital presence and trial recruitment efforts.

Funding and growth signals Revenue is modest (1–10M) with a small employee base, signaling an opportunity for strategic partners in outsourcing, manufacturing scale-up, clinical operations support, and advisory services to help accelerate development timelines.

Recent leadership movement Notable leadership changes, such as the departure of a VP from Rafael Pharmaceuticals, indicate openness to new partnerships and business development initiatives to bring in collaborative deals, licensing opportunities, or joint development arrangements to advance CPI-613.